Login to Your Account

Kidney Damage Likely Focus of Adcomm on Gilead's Quad

By Jennifer Boggs
Managing Editor

Thursday, May 10, 2012
Though FDA reviewers highlighted concerns of renal impairment in briefing documents disclosed ahead of Friday's advisory panel meeting on Gilead Sciences Inc.'s HIV drug Quad, analysts continue to expect a thumbs-up for the single-tablet regimen, comprising the active ingredients of Truvada (emtricitabine/tenofovir disoproxil fumarate) plus elvitegravir and boosting agent cobicistat.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription